Integrating leptin and cAMP pathways in triple-negative breast cancer cells

Frontiers in Bioscience

Volumn 18, Issue 1, 2013, Pages 133-144

  Spina, Annamaria ^a   Di Maiolo, Francesca ^a   Esposito, Antonietta ^a   D'Auria, Raffaella ^a   Di Gesto, Davide ^a   Chiosi, Emilio ^a   Sorvillo, Luca ^a   Naviglio, Silvio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Breast cancer; cAMP elevating agents; Novel anticancer therapy; SOCS3; STAT3

Indexed keywords

CYCLIC AMP; LEPTIN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

BREAST TUMOR; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIC AMP; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEPTIN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

MLCS; MLOWN;

EID: 84878784142     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4092     Document Type: Review

References (120)

1. American Cancer Society: Cancer Facts and Figures 2011. Atlanta, Ga: American Cancer Society, (2011)
2. U Veronesi, P Boyle, A Goldhirsch, R Orecchia and G Viale: Breast cancer. The Lancet 365(9472), 1727-1741 (2005)
3. E Hayes, RI Nicholson, S Hiscox: Acquired endocrine resistance in breast cancer: implications for tumour metastasis. Front Biosci 16, 838-848 (2011)
4. K Polyak: Heterogeneity in breast cancer. J Clin Invest 121(10), 3786-3788 (2011)
5. OI Olopade, TA Grushko, R Nanda, D Huo: Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14(24), 7988-7999 (2008)
6. EA Rakha, S Chan: Metastatic Triple-negative Breast Cancer. Clinical Oncology 587-600 (2011)
7. SK Pal, BH Childs, M Pegram: Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 125(3), 627-636 (2011)
8. Y Zhang, R Proenca, M Maffei, M Barone, L Leopold, JM Friedman: Positional cloning of the mouse obese gene and its human homologue. Nature 372(6505), 425-432 (1994)
9. MW Schwartz, DG Baskin, KJ Kaiyala, SC Woods: Model for the regulation of energy balance and adiposity by the central nervous system Am J Clin Nutr. 69(4), 584-596 (1999)
10. C Garofalo and E Surmacz: Leptin and cancer. J Cell Physiol 207(1), 12-22 (2006)
11. M Garaulet, F Perex-Llamas, T Fuente, et al: Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones. Eur J Endocrinol 143(5), 657-666 (2000)
12. N Yin, D Wang, H Zhang, X Yi, X Sun, B Shi, et al: Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res 64(16), 5870-5875 (2004)
13. M Ishikawa, J Kitayama, H Nagawa: Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res. 10(13), 4325-4331 (2004)
14. T Jardé, F Caldefie-Chezet, M Damez, et al: Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep. 19(4), 905-911 (2008)
15. F Revillion, M Charlier, V Lhotellier, et al: Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers. Clin Cancer Res. 12(7 Pt 1), 2088-2094 (2006)
16. Jr Laszlo Otvos, I Kovalszky, M Riolfi, R Ferla, J Olah, A Sztodola, K Nama, A Molino, Q Piubello, JD Wade, E Surmacz: Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer. 47(10), 1578-1584 (2011)
17. KA Frankenberry, H Skinner, P Somasundar, DW McFadden, LC Vona-Davis: Leptin receptor expression and cell signaling in breast cancer. Int J Oncol 28(4), 985-993 (2006)
18. A Ray, KJ Nkhata, MP Cleary: Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol. 30(6), 1499-1509 (2007)
19. RV Considine, MK Sinha, ML Heiman, et al: Serum immunoreactive- leptin concentrations in normal-weight and obese humans. N Engl J Med. 334(5), 292-295 1996 (Pubitemid 26033933)
20. BB Kahn, JS Flier: Obesity and insulin resistance. J Clin Invest. 106(4), 473-481 (2000)
21. KK Ryan, B Li, BE Grayson, EK Matter, SC Woods, RJ Seeley: A role for central nervous system PPAR-γ in the regulation of energy balance. Nat Med. 17(5), 623-6 (2011)
22. S Catalano, S Marsico, C Giordano, et al: Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem. 278(31), 28668-28676 (2003)
23. C Geisler, B Haynes, D Ekse, et al: Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. J Streoid Biochem Mol Biol. 104(1-2), 27-34 (2007)
24. T Jardé, S Perrier, MP Vasson, F Caldefie-Chèzet: Molecular mechanisms of leptin and adiponectin in breast cancer. European Journal of Cancer 47(1), 33-43 (2011)
25. G Paz-Filho, EL Lim, ML Wong, J Licinio: Associations between adipokines and obesity-related cancer. Front Biosci 16, 1634-1650 (2011)
26. CM Perks, JM Holly: Hormonal mechanisms underlying the relationship between obesity and breast cancer. Endocrinol Metab Clin North Am. 40(3), 485-507 (2011)
27. RR Gonzalez, S Cherfils, M Escobar, et al: Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem. 281(36), 126320-126328 (2006)
28. W Zhou, S Guo, RR Gonzalez-Perez: Leptin proangiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer. 104(1), 128-137 (2011)
29. DP Rose, EM Gilhooly, DW Nixon: Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin. Int J Oncol. 21(6), 1285-1292 (2002)
30. Y Kim, SY Kim, JJ Lee, et al: Effects of the expression of leptin and leptin receptor (OBR) on the prognosis of early-stage breast cancers. Cancer Res Treat. 38(3), 126-132 (2006)
31. M Artac, H Bozcuk, A Kiyici, OO Eren, MC Boruban, M Ozdogan: Correlation of serum leptin level and waist-to-hip ratio (WHR) with overall survival of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AIs). ASCO Annual Meetings Proceedings, Chicago (2010)
32. SW Oh, CY Park ES, Lee, et al: Adipokines, insulin resistance, metabolic syndrome, breast cancer recurrence: a cohort study. Breast Cancer Res. 13(2), R34 (2011)
33. D Cirillo, AM Rachiglio, R La Montagna, A Giordano, N Normanno: Leptin signaling in breast cancer: an overview. J Cell Biochem 105(4), 956-964 (2008)
34. M Artac, K Altundag: Leptin and breast cancer: an overview. Med Oncol (2011)
35. A Ray, MP Cleary: Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets 14(4), 443-451 (2010)
36. S Naviglio, D Di Gesto, M Romano, A Sorrentino, F Illiano, L Sorvillo, A Abbruzzese, M Marra, M Caraglia, E Chiosi, A Spina, G Illiano: Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol Ther 8(12), 1183-1190 (2009)
37. S Naviglio, D Di Gesto, F Illiano, E Chiosi, A Giordano,G Illiano, A Spina: Leptin potentiates antiproliferative action of cAMP elevation via protein kinase A down-regulation in breast cancer cells. J Cell Physiol 225(3), 801-809 (2010)
38. F Schwede, E Maronde, H Genieser, B Jastorff: Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol Ther 87(2-3), 199-226 (2000)
39. G Vitale, A Dicitore, D Mari, F Cavagnini: A new therapeutic strategy against cancer: cAMP elevating drugs and leptin. Cancer Biol Ther 8(12), 1190-1196 (2009)
40. RC Burton, RJ Bell, G Thiagarajah, C Stevenson: Adjuvant therapy, not mammographic screening, accounts for most of the observed breast cancer specific mortality reductions in Australian women since the national screening program began in 1991. Breast Cancer Res Treat. (2011)
41. C Bosetti, P Bertuccio, F Levi, L Chatenoud, E Negri, C La Vecchia.: The decline in breast cancer mortality in Europe: An update (to 2009). Breast. 21(1), 77-82 (2012)
42. C DeSantis, N Howlader, KA Cronin, A Jemal: Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers 20(5), 733-739 (2011)
43. RM O'Regan: Chemoprevention of breast cancer. The Lancet 367(9520), 1382-1383 (2006)
44. ML Kwan, LH Kushi, E Weltzien, et al: Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11(3), R31 (2009)
45. BG Haffty, Q Yang, M Reiss, et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36), 5652-5657 (2006)
46. EA Rakha, JS Reis-Filho, IO Ellis: Basal-like breast cancer: a critical review. J Clin Oncol 26(15), 2568-2581 (2008)
47. EA Rakha, ME El-Sayed, AR Green, et al: Prognostic markers in triple-negative breast cancer. Cancer 109(1), 25-32 (2007)
48. MC Cheang, D Voduc, C Bajdik, et al: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5), 1368-1376 (2008)
49. EA Rakha, ME El-Sayed, AR Green, et al: Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25(30), 4772-4778 (2007)
50. A Prat, J Baselga: The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with coexpression of HER2. Nat Clin Pract Oncol 5(9), 531-542 (2008)
51. MC Cheang, SK Chia, D Voduc, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10), 736-750 (2009)
52. YW Moon, S Park, JH Sohn, DR Kang, JS Koo, HS Park, HC Chung, BW Park: Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol 137(7), 1123-1130 (2011)
53. E Azambuja, V Durbecq, DD Rosa, et al: HER-2 overexpression/ amplification and its interaction with taxane based therapy in breast cancer. Ann Oncol 19(2), 223-232 (2008)
54. R Dent, M Trudeau, KI Pritchard, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13(15 Pt 1), 4429-4434 (2007)
55. KB Reddy: Triple-negative breast cancers: an updated review on treatment options. Curr Oncol. 18(4), 173-179 (2011)
56. SM Domchek, G Mitchell, GJ Lindeman, NM Tung, J Balmaña, SJ Isakoff, R Schmutzler, MW Audeh, N Loman, C Scott, M Friedlander, B Kaufman, JE Garber, A Tutt, ME Robson: Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From BRCA1/2-Associated Breast Cancer. J Clin Oncol. 29(32), 4224-4226 (2011)
57. GA Robison, RW Butcher, EW Sutherland: Cyclic AMP. Annu Rev Biochem 37, 149-174 (1968)
58. J Hanoune, N Defer: Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41, 145-174 (2001)
59. K Omori, J Kotera: Overview of PDEs and their regulation. Circ Res. 100(3), 309-327 (2007)
60. S Naviglio, M Caraglia, A Abbruzzese, E Chiosi, D Di Gesto, M Marra, et al: Protein kinase A as a biological target in cancer therapy. Expert Opin Ther Targets 13(1), 83-92 (2009)
61. J De Rooij, FJ Zwartkruis, MH Verheijen et al: Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396(6719), 474-477 (1998)
62. PJ Stork, JM Schmitt: Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 12(6), 258-266 (2002)
63. M Gloerich, JL Bos: Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol 50, 355-375 (2010)
64. PA Insel, L Zhang, F Murray, H Yokouchi, AC Zambon: Cyclic AMP is both a pro-apoptotic and antiapoptotic second messenger. Acta Physiol (Oxf) (2011)
65. AC Zambon, A Wilderman, A Ho, PA Insel: Increased expression of the pro-apoptotic protein BIM, a mechanism for cAMP/protein kinase A (PKA)-induced apoptosis of immature T cells. J Biol Chem. 286(38), 33260-33267 (2011)
66. BS Skalhegg and K Tasken: Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci 5, D678-D693 (2000)
67. JA Beavo, LL Brunton: Cyclic nucleotide research-still expanding after half a century. Nat Rev Mol Cell Biol 3(9), 710-718 (2002)
68. S Naviglio, M Pagano, M Romano, A Sorrentino, A Fusco, F Illiano, E Chiosi, A Spina, G Illiano: Adenylate cyclase regulation via proteasome-mediated modulation of Galphas levels. Cell Signal 16(11), 1229-1237 (2004)
69. S Naviglio, A Spina, E Chiosi, A Fusco, F Illiano, M Pagano, M Romano, G Senatore, A Sorrentino, L Sorvillo, G Illiano Inorganic phosphate inhibits growth of human osteosarcoma U2OS cells via adenylate cyclase/cAMP pathway. J Cell Biochem 98(6), 1584-1596 (2006)
70. AM El-Mowafy, M Alkhalaf: Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis. 24(5), 869-873 (2003)
71. M Zaccolo and Pozzan, T: Discrete Microdomains with High Concentration of cAMP in Stimulated Rat Neonatal Cardiac Myocytes. Science 295(5560), 1711-1715 (2002)
72. D Willoughby, DM Cooper: Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev. 87(3), 965-1010 (2007)
73. K Simons, E Ikonen: Functional rafts in cell membranes. Nature 387(6633), 569-572 (1997)
74. R Savai, SS Pullamsetti, GA Banat, N Weissmann, HA Ghofrani, F Grimminger, RT Schermuly: Targeting cancer with phosphodiesterase inhibitors. Expert Opin Investig Drugs 19(1), 117-131 (2010)
75. DL Beene, JD Scott: A-kinase anchoring proteins take shape. Curr Opin Cell Biol 19(2), 192-198 (2007)
76. YS Cho-Chung, T Clair, JS Bodwin and B Berghoffer: Growth arrest and morphological change of human breast cancer cells by dibutyryl cyclic AMP and L-arginine. Science 214(4516), 77-79 (1981)
77. J Chen, JA Bander, TA Santore, Y Chen, PT Ram, MJ Smit et al: Expression of Q227L-G alphas in MCF-7 human breast cancer cells inhibits tumorigenesis. PNAS 95(5), 2648-2652 (1998)
78. SN Kim, YH Ahn, SG Kim, SD Park, YS Cho-Chung, SH Hong: 8-Cl-cAMP induces cell cycle-specific apoptosis in human cancer cells. Int J Cancer 93(1), 33-41 (2001)
79. TA Santore, Y Chen, MJ Smit and R Iyengar: Adenovirus-directed expression of Q227L-Galpha s inhibits growth of established tumors of later-stage human breast cancer cells in athymic mice. PNAS 99(3), 1671-1676 (2002)
80. D Katsaros, G Tortora, P Tagliaferri, T Clair, S Ally, L Neckers, RK Robins, YS Cho-Chung: Site-selective cyclic AMP analogs provide a new approach in the control of cancer cell growth. FEBS Lett 223(1), 97-103 (1987)
81. K Iwatsubo, S Okumura, Y Ishikawa. Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling. Endocr Metab Immune Disord Drug Targets 6(3), 239-247 (2006)
82. C Lugnier: Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109(3), 366-398 (2006)
83. G Castoria, A Migliaccio, L D'Amato, R Di Stasio, A Ciociola, M Lombardi, et al: Integrating signals between cAMP and MAPK pathways in breast cancer. Front Biosci 13, 1318-1327 (2008)
84. NE Bhola, JR Grandis: Crosstalk between G-protein-coupled receptors and Epidermal growth factor receptor in cancer. Front Biosci 13, 1857-1865 (2008)
85. JY Kato, M Matsuoka, K Polyak, J Massagué, CJ Sherr: Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 79(3), 487-496 (1994)
86. P Tan, B Cady, M Wanner, P Worland, B Cukor, C Magi-Galluzzi, et al: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57(7), 1259-1263 (1997)
87. CL Neary, M Nesterova, YS Cho-Chung et al: Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion. Oncogene 23(54), 8847-8856 (2004)
88. WR Miller: Regulatory subunits of PKA and breast cancer. Ann N Y Acad Sci 968, 37-48 (2002)
89. W Loilome, S Juntana, N Namwat, V Bhudhisawasdi, A Puapairoj, B Sripa, M Miwa, H Saya, GJ Riggins, P Yongvanit: PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma. Int J Cancer Jul 129(1), 34-44 (2011)
90. RK Srivastava, AR Srivastava, SJ Korsmeyer, M Nesterova, YS Cho-Chung, DL Longo: Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 18(6), 3509-3517 (1998)
91. KS Sastry, Y Karpova, S Prokopovich, AJ Smith, B Essau, A Gersappe, et al: Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem 282(19), 14094-14100 (2007)
92. F Chiaradonna, C Balestrieri, D Gaglio, M Vanoni: RAS and PKA pathways in cancer: new insight from transcriptional analysis. Front Biosci. 13, 5257-78 (2008)
93. M Safa, A Kazemi, H Zand, A Azarkeivan, F Zaker, P Hayat: Inhibitory role of cAMP on doxorubicin-induced apoptosis in pre-B ALL cells through dephosphorylation of p53 serine residues. Apoptosis 15(2), 196-203 (2010)
94. H Yokozaki, G Tortora, S Pepe, E Maronde, HG Genieser, B Jastorff, YS Cho-Chung: Unhydrolyzable analogues of adenosine 3,5-monophosphate demonstrating growth inhibition and differentiation in human cancer cells. Cancer Res 52(9), 2504-2508 (1992)
95. B Del Valle-Pérez, OM Martínez-Estrada, S Vilaró, F Ventura, F Viñals: cAMP inhibits TGFbeta1-induced in vitro angiogenesis. FEBS Lett 569(1-3), 105-111 (2004)
96. C Bianco, G Tortora, G Baldassarre, R Caputo, G Fontanini, S Chinè, AR Bianco, F Ciardiello: 8-Chloro-cAMP inhibits autocrine and angiogenic growth factors production in human colorectal and breast cancer. Clin Cancer Res 3(3), 439-448 (1997)
97. A Dittmer, M Vetter, D Schunke, PN Span, F Sweep, C Thomssen, J Dittmer: Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells. J Biol Chem. 281(21), 14563-14572. (2006)
98. Y Radestock, C Hoang-Vu, S Hombach-Klonisch: Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells. Breast Cancer Res. 10(4), R71 (2008)
99. L Chen, JJ Zhang, XY Huang: cAMP inhibits cell migration by interfering with Rac-induced lamellipodium formation. J Biol Chem. 283(20), 13799-13805 (2008)
100. C Hansen, J Howlin, A Tengholm, O Dyachok, WF Vogel, AC Nairn, P Greengard, TJ Andersson: Wnt-5a-induced phosphorylation of DARPP-32 inhibits breast cancer cell migration in a CREB-dependent manner. Biol Chem. 284(40), 27533-27543. (2009)
101. J Son, JH Lee, HN Kim, H Ha, ZH Lee: cAMP-response-element-binding protein positively regulates breast cancer metastasis and subsequent bone destruction. Biochem Biophys Res Commun 398(2), 309-314 (2010)
102. G Fruhbeck:Intracellular signaling pathways activated by leptin. Biochem J 393(1), 7-20 (2006)
103. KJ Nkhata, A Ray, TF Schuster, ME Grossmann, MP Cleary: Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep 21(6), 1611-1619 (2009)
104. CN Perera, HG Chin, N Duru, IG Camarillo: Leptin-regulated gene expression in MCF-7 breast cancer cells: mechanistic insights into leptin-regulated mammary tumor growth and progression. J Endocrinol 199(2), 221-233 (2008)
105. JA, McCubrey, LS Steelman, WH Chappell, SL Abrams, EW Wong, F Chang, B Lehmann, DM Terrian, M Milella, A Tafuri, F Stivala, M Libra, J Basecke, C Evangelisti, AM Martelli, RA Franklin: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773(8), 1263-1284 (2007)
106. S Naviglio, A Spina, M Marra, et al: Adenylate cyclase/cAMP pathway downmodulation counteracts apoptosis induced by IFN-alpha in human epidermoid cancer cells. J Interferon Cytokine Res 27(2), 129-36 (2007)
107. S Kostenko, A Shiryaev, G Dumitriu, N Gerits, U Moens: Cross-talk between protein kinase A and the MAPK-activated protein kinases RSK1 and MK5. J Recept Signal Transduct Res. 31(1), 1-9(2010)
108. E Fiorio, A Mercanti, M Terrasi, et al: Leptin/HER2 crosstalk in breast cancer: in vitro study, preliminary in vivo analysis. BMC Cancer 8, 305 (2008)
109. RH Alvarez, V Valero, GN Hortobagyi: Emerging targeted therapies for breast cancer. J Clin Oncol. 28(20), 3366-3379 (2010)
110. N Jing and DJ Tweardy: Targeting Stat3 in cancer therapy. Anticancer Drugs 16(6), 601-607 (2005)
111. D Germain and DA Frank: Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 13(19), 5665-5669 (2007)
112. PA Johnston, JR Grandis: STAT3 signaling: anticancer strategies and challenges. Mol Interv. 11(1), 18-26 (2011)
113. NA Binai, A Damert, G Carra, S Steckelbroeck, J Löwer, R Löwer, S Wessler: Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells. Int J Cancer 127(1), 55-66 (2010)
114. SH Kim, A Nagalingam, NK Saxena, SV Singh, D Sharma: Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3. Carcinogenesis 32(3), 359-367 (2010)
115. D McCormack, J Schneider, D McDonald, D McFadden: The antiproliferative effects of pterostilbene on breast cancer in vitro are via inhibition of constitutive and leptin-induced Janus kinase/signal transducer and activator of transcription activation. Am J Surg. 202(5), 541-544 (2011)
116. VA Nguyen and B Gao: Cross-talk between alpha(1B)-adrenergic receptor (alpha(1B)AR) and interleukin-6 (IL-6) signaling pathways. Activation of alpha(1b)AR inhibits il-6-activated STAT3 in hepatic cells by a p42/44 mitogen-activated protein kinase-dependent mechanism. J Biol Chem 274(50), 35492-35498 (1999)
117. JL Barclay, ST Anderson, MJ Waters, JD Curlewis: Characterization of the SOCS3 promoter response to prostaglandin E2 in T47D cells. Mol Endocrinol. 21(10), 2516-2528 (2007)
118. HD, Woolson VS Thomson, C Rutherford, SJ Yarwood, TM Palmer: Selective inhibition of cytokine-activated extracellular signal-regulated kinase by cyclic AMP via Epac1-dependent induction of suppressor of cytokine signalling-3. Cell Signal. 21(11), 1706-1715 (2009)
119. BA Croker, H Kiu and SE Nicholson: SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 19(4), 414-422 (2008)
120. S Wormald, DJ Hilton: Inhibitors of cytokine signal transduction. J Biol Chem 279(2), 821-824 (2004)